drugset / Trial / NCT06765954
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
NaSingle-groupOpen-labelTreatment
Summary
This study tests a new treatment for men with high-risk prostate cancer who can't have surgery. The treatment combines three experimental drugs and radiation therapy. Researchers will track how well the treatment works and how safe it is. The study will last about five years.
Timeline
- Start
- 2025-12-01
- Primary completion
- 2031-01-31
- Completion
- 2031-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ETBX-071 | Vaccine | — | Subcutaneous |
| Subject | M-CENK | Cell therapy | — | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | — | Subcutaneous |